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ABSTRACT
Objective To provide estimates of mortality among
HIV-infected patients starting combination antiretroviral
therapy.
Methods We report on the death rates from 122 925
adult HIV-infected patients aged 15 years or older from
East, Southern and West Africa, Asia Pacific and Latin
America. We use two methods to adjust for biases in
mortality estimation resulting from loss from follow-up,
based on double-sampling methods applied to patient
outreach (Kenya) and linkage with vital registries (South
Africa), and apply these to mortality estimates in the
other three regions. Age, gender and CD4 count at the
initiation of therapy were the factors considered as
predictors of mortality at 6, 12, 24 and >24 months
after the start of treatment.
Results Patient mortality was high during the first
6 months after therapy for all patient subgroups and
exceeded 40 per 100 patient years among patients who
started treatment at low CD4 count. This trend was seen
regardless of region, demographic or disease-related risk
factor. Mortality was under-reported by up to or
exceeding 100% when comparing estimates obtained
from passive monitoring of patient vital status.
Conclusions Despite advances in antiretroviral
treatment coverage many patients start treatment at very
low CD4 counts and experience significant mortality
during the first 6 months after treatment initiation. Active
patient tracing and linkage with vital registries are critical
in adjusting estimates of mortality, particularly in low-
and middle-income settings.
INTRODUCTION
Thirty years after the first description of the AIDS,
cases of the disease have been observed in every
part of the world. More than 33 million indivi-
duals are infected with the majority of them living
in low- and middle-income countries.1 However,
there are also positive statistics. According to the
same report, new infections have been reduced by
19% since 1999. In addition, up to 5.2 million
people in low- and middle-income countries were
receiving care in 2009, 1.2 million of whom started
therapy for the first time in that year; a significant
30% increase compared with only a year before.
Still, this only represents just over a third of all
persons, 15 million by some estimates, who need
therapy now.
Regardless of the enormity of this challenge,
it is obvious that we are witnessing a historic
undertaking with rapid scale-up of services provid-
ing antiretroviral therapy (ART) to millions of
HIV-infected individuals, particularly in resource-
limited parts of the world. By all accounts, the
largest pharmacological intervention in human
history has reduced rates of opportunistic infec-
tions, increased survival and enhanced the quality
of life of the recipients of these services.2 3
Nevertheless, it is clear that the impact of therapy
is not the same across all groups of patients living
with HIV/AIDS or all regions of the world.2 For
example, mortality is higher among patients with
greater suppression of their immune system as
indicated by lower CD4 lymphocyte levels at the
start of therapy despite access to treatment4 and
response to therapy may not be as strong com-
pared with patients with higher CD4 counts.5 6
Gender and age play a role as well. In resource-
constraint settings, men generally access treatment
later than women7 and may be less compliant to
therapy once initiated.8–10 Also, the disease may
affect younger and older patients differently.11 12
Thus, assessment of treatment efficacy, pro-
gramme evaluation and policy making should, at a
minimum, take these disease-specific and demo-
graphic factors into account.
One core component for assessing programme
and treatment effectiveness is the estimation of
patient mortality, especially among those patients
who initiate ART. These estimates will in turn
inform policy makers, modellers, epidemiologists
and other stakeholders involved with antiretroviral
programmes throughout the world. There are a
number of advantages in considering mortality as
the primary patient outcome. Mortality is the
ultimate endpoint by which to evaluate the effect-
iveness of an intervention when, as is the case
with HIV infection, the disease represents a grave
risk to the survival of the patient. Another advan-
tage is the unequivocal nature of the death as an
outcome (as opposed to diagnosing a bacterial
infection, for example). However, significant chal-
lenges remain. In all settings, but particularly in
low- and middle-income countries, a substantial
number of patients starting therapy are lost from
observation. In one review covering a number of
countries in sub-Saharan Africa, between a quarter
and half of all patients who started therapy were
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lost after 2 years from starting therapy.13 Two reports from
patient cohorts in the US and the UK also cited high levels of
patient loss14 15 suggesting that this phenomenon is not
limited to resource-limited settings. Moreover, it appears that,
at least in sub-Saharan Africa, the risks for mortality overlap to
a large extent with the risks of loss from follow-up16 17 and
that the hardest to reach patients may also be those at the
highest risk of mortality.18 Thus, it comes as no surprise that
programmes which undertake more intensive efforts to locate
patients who have been lost have higher levels of mortality.2
The immediate consequence of all these considerations is that
mortality estimates will be negatively biased when derived
exclusively from information on deaths obtained passively
among patients who were maintained under observation until
the end. The result is a potentially significant underestimation
of the true death rates in reports which are based solely on
passive death information.
Recently, mathematical models originally developed to
address issues of informative dropout in studies of survival
have been adapted to the context of ongoing epidemiological
cohorts with similar non-random losses from follow-up.16 17 19
These efforts are emanating from the work on double sampling20
by Frangakis and Rubin21 and inverse probability of treatment
weighting schemes introduced by Robins and others.22 23 They
are based on the availability of vital status information on a
random sample of patients among those who have been lost to
follow-up (the second or ‘double’ sample). The methodology
weighs those lost patients with available vital status informa-
tion by the inverse of their number over all patients who were
lost. In this manner, a pseudo dataset is constructed where the
actively sought patients, including all deaths thus ascertained,
represent themselves as well as all other patients who were lost
but were not sought. Patients who remain on observation or
have died (and their death has been recorded passively, without
resorting to outreach methods) are weighted by one (ie, they
only represent themselves). In this manner, an adjustment of
the mortality estimate is made. It can result in dramatically
higher mortality estimates because the hazard of mortality
among patients lost to follow-up can be over 10 times higher
compared with the hazard among patients who remain under
observation.17 19
Information on the vital status of a sample of patients who
are lost to follow-up can be obtained in one of two ways. First,
a random sample of the individuals who were lost to follow-up
can be traced employing methods such as telephone calls and
home visits to establish whether the patient is still alive. In
sub-Saharan Africa, there are a number of cohorts employing
patient outreach programmes, which trace a significant propor-
tion of lost patients.24 25 A second way to determine patient
vital status is through national vital registration systems. The
latter approach is only feasible if two conditions are met: (1) a
reasonably high proportion of deaths are recorded and (2) that
health facilities capture the information required for the
purpose of linking the patient to the vital registration system.
In sub-Saharan Africa, South Africa is one of few countries in
which the first condition is met26 with around 90% of all adult
deaths recorded.27 The second condition is met only in a subset
of South African ART cohorts. In those cohorts, the lost
patients who can be successfully located in the death registries
can then be treated in exactly the same way as successfully
located patients who are physically traced after loss to
follow-up. This means that the patients with identity numbers
who are lost to follow-up are ‘weighted up’ to represent other
lost-to-follow-up patients without identity numbers.28
Unfortunately, access to death registries is the exception
rather than the rule in low- and middle-income countries. In
addition, there are few sufficiently documented outreach pro-
grammes. This is because the goal of most outreach pro-
grammes is to locate as many patients as possible in order to
reinstate them into care rather than to perform a public health
evaluation or attempt to mathematically adjust mortality esti-
mates in their patient population. In many cases, the public
health value of documenting patient encounters in the process
of outreach is not clear to even mature care and treatment pro-
grammes. To overcome this problem, a number of intermediate
or hybrid methods have recently been proposed. For example,
when outreach data are not available but there is information
about the HR between the observed versus lost patients (pos-
sibly through outreach programmes at sentinel sites in the
same country or region), the mortality of the latter subcohort
can be imputed.29 In other cases, one may rely on the observa-
tion that programmes with high rates of losses to follow-up
also have lower HRs for mortality between patients who are
lost and those who remain under observation. This has been
observed in a number of instances throughout sub-Saharan
Africa where rapid scale-up of care and treatment services
result in often chaotic patient self-referral patterns from one
clinic to another, which accounts for an increasing proportion
of losses to follow-up.30 Using a structured survey of a number
of programmes throughout the region, Egger and colleagues
constructed a nomogram where a correction factor is estimated
according to the mortality ratio between patients who were
lost or not and the level of loss to follow-up at a particular pro-
gramme.31 This correction factor is then used to produce
adjusted estimates of 1-year mortality.
Death is thus an unequivocal measure of effectiveness of the
care and treatment provided, particularly in the context of a
fatal disease. Patient survival also affects a number of down-
stream economic and HIV-related factors, such as disease preva-
lence and incidence rates, the productivity of entire societies
and so on. Thus, accurate estimation of mortality impacts
numerous aspects of scientific enquiry as well as public health
policy. This survey paper uses established mathematical model-
ling methodologies to provide estimates of mortality in
HIV-infected patients starting ART by assembling data from a
number of cohorts of patients receiving routine medical care
and ART in a number of programmes around the world.
Although we provide brief description of the methods, our
main goal is to provide as geographically complete coverage of
the world as possible and thus describe the burden of mortality
in a number of world regions.
METHODS
Description of cohorts involved in the study
In this paper, we report on five regional cohorts with available
patient-level data needed for estimation of mortality in adult
HIV-infected patients starting ART: East, Southern and West
Africa, Asia Pacific and Latin America.32–36 All five are members
of the worldwide International Epidemiologic Databases to
Evaluate AIDS (IeDEA) Collaboration, a consortium created to
aggregate epidemiological data from HIV regional cohorts
around the world. The first of these five IeDEA cohorts is a
network of 23 main care and treatment clinics and several satel-
lite clinics comprising the partnership between the United
States Agency for International Development and the
Academic Model Providing Access to Healthcare (the
USAID-AMPATH partnership), located in western Kenya. This
cohort includes data obtained from a large number of patients
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initially lost from follow-up who were subsequently success-
fully located through AMPATH’s massive patient outreach pro-
gramme.16 17 The second cohort is comprised of nine care
and treatment facilities in the Republic of South Africa.
These cohorts are unique in our study as they have well-
documented linkages with vital registries and information
recovered from these linkages has been used to adjust estimates
of mortality in these cohorts.28 The third, fourth and fifth
cohorts comprise care and treatment programmes in West
Africa36 and Asia Pacific, made up of the Therapeutics
Research, Education, and AIDS Training in Asia (TREAT Asia)
Study to Evaluate Resistance and the TREAT Asia HIV
Observational Database,34 37 and three Latin American cohorts
participating in the Caribbean, Central and South American
Network.33
Inclusion criteria
Data from all cohorts were obtained through routine clinical
care of HIV-infected patients. Inclusion criteria were minimal,
specifying simply that the patients were adult (aged
>15 years) HIV-infected men and women who were ART
naive at enrolment (except for limited previous exposure to
antiretrovirals for prevention of mother-to-child HIV transmis-
sion) and who initiated first-line ART in any participating site
within the cohort. Further detail on prevailing first-line regi-
mens at each region is given in the Results section in the sub-
section related to each of the five cohorts comprising this
study. While second-line treatment regimens are becoming
increasingly available in many low- and middle-income set-
tings, the prevalence of second-line therapy is still relatively
low, particularly within the sub-Saharan African regions. Even
though information on treatment switches to second-line
therapy was available in a number of cohorts, we chose not to
include this information in the mortality calculations both for
simplicity of the modelling and because our main objective in
this study was to assess the levels of mortality of a typical
HIV-infected patient starting first-line ART in these settings.
Data collected
Data included demographic information such as gender and
age. Age was grouped into four categories spanning 15–24,
25–34, 35–44 and ≥45 years. In addition to information on
gender and age at initiation of ART, data included all landmark
dates of each patient’s treatment history, such as the date of
ART initiation, the date of the last clinic visit, the date of
death and the date of the most recent outreach encounter
when applicable. A number of indicators were included in the
data such as whether the patient died, whether the patient
death was ascertained via passive means or through patient
outreach and whether the patient had been lost to follow-up.
Loss to follow-up was defined as having no clinical visits for
more than 6 months. Gaps in care, where a patient discontin-
ued attending the clinic for some time but subsequently
returned to care, were not considered as losses to follow-up. On
the other hand, patients who were outreached were essentially
treated as having been lost to follow-up regardless of the length
of time between their last visit and the outreach encounter
date as, once traced successfully, their loss to follow-up status
would never be determined with certainty.17 This only applies
to cohorts with documented outreach programmes (Kenya) or
established linkages to vital registries (South Africa).
CD4 count at ART initiation was defined as the CD4 count
available within 6 months before (strictly speaking 182 days
before) and 14 days after initiation of therapy (the latter to
ensure inclusion of CD4 counts which were obtained contem-
poraneously with the start of treatment but were recorded
with a small delay). If there were multiple CD4 measurements
during this period, then the one closest to the start date of
ART was selected. The CD4 categories used were <50, 50–99,
100–199, 200–249, 250–349, 350–499 and ≥500 cells/μl.
Mathematical models of patient mortality
We adjusted mortality estimates for the East Africa data using
methods based on double sampling of physically located
patients who were lost to follow-up.16 17 For South African
data, we used similar methods, but lost patients were instead
‘searched’ in the death registries of the country.28 Only pas-
sively determined death information was available in all other
cohorts. For these cohorts, we used a modification of the
approach by Brinkhof and colleagues,5 which uses inflation
factors to increase mortality under-reporting. Death rates based
on observed data only were estimated for each patient subgroup
defined by gender as well as age and CD4 category. These
passive mortality estimates were then multiplied by a group-
specific inflation factor determined as the ratio of the
outreach-adjusted death rates over the observed rates estimated
within the Kenyan and South African cohorts. This calculation
resulted in two adjusted estimates of mortality—one using
Kenyan data and the other using South African data—for
cohorts where patient outreach was not available. This
approach also addresses a number of limitations in the nomo-
gram approach proposed by Egger and colleagues38 in that it
provides specific adjustments for all subgroups defined by
gender, age and CD4 count as well as generating adjusted esti-
mates past 1 year after ART initiation.
A final detail concerns the two-phase nature of the mortality
hazard after initiation of ART. As has been widely published,
the first 3–6 months after ART initiation are critical for the sur-
vival of the patient.31 39 In this analysis, we used a piece-wise
exponential model fit through Poisson regression. Four distinct
intervals were defined at 0–6, 6–12, 12–24 and >24 months.
This model assumes constant hazards of mortality in each
interval (although these are allowed to vary from interval to
interval). The period between 0 and 6 months was modelled
separately from later periods to address the uniqueness of the
early post-treatment period of high mortality.39 Although this
is a rather limited model in describing the changes in mortality
which occurs after initiation of ART, it is useful because it is
easy to implement and even easier to describe to stakeholders
and decision makers involved with antiretroviral programmes
around the world. Adjustments for dropout were handled by
weighting according to the Frangakis and Rubin approach19 to
account for the increased HR between patients who were lost
to follow-up versus those retained in care and under observa-
tion (see online supplementary appendix for further details of
the modelling approach and the code used for model fitting).
RESULTS
This study encompasses five IeDEA regional cohorts from East,
Southern and West Africa, Asia Pacific and Latin America.
A total of 122 925 adult HIV-infected patients aged 15 years or
older were included. From East Africa, the USAID-AMPATH
cohort provided data from 32 217 adult patients while in the
Southern Africa region, data from 48 046 patients were
included from nine care and treatment cohorts in the Republic
of South Africa. The West Africa IeDEA regional cohort was
comprised of 15 cohorts from Benin, Côte d’Ivoire, Senegal,
Gambia, Mali and Nigeria and contributed a total of 33 005
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patients. The Asia Pacific regional cohort contributed 6106
patients from 13 countries including Cambodia, China,
Hong Kong, Japan, India, Indonesia, Malaysia, the Philippines,
Singapore, South Korea, Taiwan, Thailand and Vietnam. The
regional cohort from Latin America contributed 3551 patients
from Argentina, Brazil and Mexico.
The most commonly used first-line ARTregimen in Kenya and
South Africa is Stavudine (D4T) and Lamivudine (3TC) with
either Nevirapine (NVP) or Efavirez (EFV). In Latin America, the
most frequent combination is Zidovudine (AZT), 3TC and EFV.
The second most common drug combination is Tenofovir (TDF)
with Emtricitabine and EFV. In the Asia Pacific region, among
developing countries, first-line therapy usually amounts to a com-
bination of AZT or D4T plus 3TC with NVP or EFV, often as a
generic drug similar to Africa, with a slow recent move towards
TDF. In the developed countries (Japan, Hong Kong, Taiwan,
Table 1 Number of patients by gender and age category
Gender Age category
Clinic site Females N (%) 15–24 25–34 35–44 45+ Total
East Africa
Kenya
USAID-AMPATH 20 601 (63.9) 1765 11 359 11 942 7151 32 217
Southern Africa
South Africa 27 791 (58.5)
Aurum Institute (community) 661 4300 3953 2069 10 983
Aurum Institute (work place) 64 1231 1829 2164 5288
Gugulethu Clinic 233 1177 700 282 2392
Hlabisa HIV treatment and care programme 808 3424 2775 1742 8749
Khayelitsha ART Programme 667 3152 1841 653 6313
Masiphumelele Clinic 82 295 126 52 555
McCord Hospital 158 1185 918 427 2688
Themba Lethu Clinic 585 4199 3567 1644 9995
Tygerberg Hospital 90 483 343 167 1083
West Africa
Benin
CNHU Hubert H. Maga 496 (57.2) 56 310 309 192 867
Côte d’Ivoire 9738 (63.0)
CePReF 243 1652 1520 826 4241
CNTS 65 455 417 220 1157
USAC, CHU de Treichville 151 1074 1093 644 2962
MTCT Plus 52 326 118 22 518
CIRBA 122 967 1127 767 2983
SMIT, CHU de Treichville 145 1377 2082 1140 4744
Burkina Faso
CHU de Yaldago 1164 (68.8) 75 549 689 380 1693
Senegal 468 (55.8)
SMIT Dakar 17 134 152 132 435
ANRS 1215, Dakar 23 136 155 90 404
Gambia
Fajara 140 (64.5) 9 61 81 66 217
Mali 1403 (62.3)
Gabriel Touré 146 583 516 318 1563
CHU de Point G 58 238 253 139 688
Nigeria 6756 (64.1)
University of Abuja 435 2036 1519 1068 5058
University of Benin 298 1965 1523 1689 5475
Asia Pacific
TAHOD 1232 (29.2) 290 1901 1375 658 4224
TASER 565 (30.0) 133 683 655 411 1882
Latin America
Argentina
Fundación Huésped 458 (30.3) 90 665 530 226 1511
Brazil
Fundação Oswaldo Cruz 419 (33.3) 97 466 421 274 1,258
Mexico
INNSZ 87 (11.1) 90 332 236 124 782
AMPATH, Academic Model Providing Access to Healthcare; ANRS, Agence nationale de recherché sur le sida; CHU, Centre Hospitalier Universitaire de Treichville (Côte d’Ivoire); CIRBA,
Centre Intégré de recherché biocliniques d’Abidjan; CNHU, Centre Hospitalier Universitaire (Benin); CNTS, Centre national de transfusion sanguine; IeDEA, International Epidemiologic
Databases to Evaluate AIDS; MTCT, mother-to-child transmission; SMIT, Service de Médecine Interne et Tropicale; TAHOD, TREAT Asia HIV Observational Database; TASER, TREAT ASIA
Study to Evaluate Resistance; USAC, Unité de soins, d’accueil et de conseils pour les sidéens; USAID, US Agency for International Development.
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Korea), first-line therapy would be a triple combination including
an non-nucleoside reverse-transcriptase inhibitor or a protease
inhibitor as in Europe, North America and Australia.
Baseline characteristics
A listing of the cohorts and the overall number of patients by
gender and age category is given in table 1. The first impression
from this table is that, while the epidemic in Africa is rather
homogeneous and affects women in a roughly 2:1 ratio com-
pared with men, the reverse is true in the Asia Pacific and Latin
America where the epidemic is driven primarily by men.
Loss-to-follow-up rates were high in all African cohorts
(table 2). Annualized rates of loss to follow-up were over 20%
during the first 6 months after ART initiation in the East and
Southern Africa cohorts, with annualized rates of loss staying
close to 10% during the second 6 months and stabilizing at that
level thereafter. Losses to follow-up were almost double in West
African cohorts, with annualized rates over 35% during the first
6 months after treatment initiation and remaining above 20%
thereafter. Losses to follow-up were much lower in the Asia
Pacific and Latin American cohorts, where annualized rates were
8% and just over 10% for patients after starting ART. These
observations will be useful later when speculating about the
applicability to these regions the results derived from cohorts in
sub-Saharan Africa.
The distribution of CD4 count at ART initiation by gender
and region is shown in figure 1. As it is widely reported,7 40
women have higher CD4 counts at the time of ART initiation,
the result of both early detection as well as complex healthcare
access differences between the sexes, particularly in resource-
limited settings.
Estimates of mortality
In the next subsection, we summarise the results from the two
cohorts with available data on patient outreach (Kenya) and
vital registry linkages (South Africa) as these data are amenable
to mathematical adjustment of the mortality estimates. We
proceed with a summary of the mortality estimates in the
remaining three cohorts in the following subsection.
The Kenyan and South African cohorts
Mortality was estimated as described in the Methods Section
at the critical first 6 months after the start of ART, 6–12, 12–24
and >24 months. Adjustments were based on 2409 successful
outreach encounters in the Kenya cohort, out of 7252 patients
who were lost to follow-up and 4602 individuals successfully
linked out of 9167 persons who were lost to follow-up in the
South African cohort. The adjusted estimates of mortality by
age and CD4 category for male and female subjects are given in
figure 2 for the Kenyan and South African cohorts. The imme-
diate impression upon inspection of these figures is the high
death rates in the first 6 months after initiation of ARTand the
significant reduction of these rates during subsequent periods.
In order to appreciate the impact of the adjustments from
information obtained through patient outreach (Kenya) and
vital records (South Africa), we provide the correction factors
defined as the ratios of the adjusted to the unadjusted death
rates in each age, gender and CD4 category. These data are pre-
sented in figure 3. The implication of the results, as shown in
figure 3, is that the adjustment of the death rates is both sub-
stantial and variable among genders, age groups, CD4 categor-
ies as well as cohorts. A major difference between the Kenyan
and South African cohort is that, in the Kenyan cohort, the
adjustments are the highest particularly during the first
6 months after ART initiation when they can reach 60%.
Correction factors are even higher among South African
cohorts where adjustments are almost 70% during the first
6-month period. In subsequent periods, the adjustments are
even higher, sometimes over 100%, but their absolute effect is
limited due to the low death rates during these periods. In the
South African cohort, the highest adjustments involve the
highest CD4 category (above 500 cells/μl). This suggests a pos-
sibly unique mortality pattern for this group.
The West African, Asia Pacific and Latin American cohorts
As mentioned in the Mathematical models section, many
cohorts considered for this analysis have no outreach of
patients and thus adjustments of patient mortality are impos-
sible. We borrowed from the idea underlying the nomogram
approach published by Egger and colleagues31 but adjusted it
to fit the needs of the current project. The nomogram
approach considers the inverse relationship between the size
of lost to follow-up (LTFU) and per cent of LTFU patients
who are dead in order to extrapolate the correct (but
unknown) death rate among patients who drop out from care.
In the original paper by Egger and colleagues, estimates of
1-year mortality after initiating ART were produced.31
However, here, we want to estimate mortality at 0–6, 7–12,
13–24 and >24 months from ART initiation in a large number
of groups, where we cannot reasonably assume that the same
correction factor holds. Thus, we used, as an estimate of the
correction factor between LTFU patients and patients under
observation in the paper by Egger and colleagues, the ratio of
adjusted and crude death rates estimated in the East African
(not shown) and South African cohorts for all the subgroups
Table 2 Loss to follow-up rates in the five regions involved in the
analyses
Male Female Total
ART duration (months) N Rate N Rate Total Rate
East Africa
0–6 1053 0.2340 1686 0.2079 2739 0.2172
6–12 394 0.1128 757 0.1189 1151 0.1168
12–24 434 0.0908 832 0.0951 1266 0.0941
>24 246 0.0765 466 0.0793 712 0.0783
South Africa
0–6 1891 0.2331 2138 0.1796 4029 0.2013
6–12 665 0.1058 798 0.0852 1463 0.0935
12–24 913 0.1053 992 0.0782 1905 0.0892
>24 955 0.1230 815 0.0897 1770 0.1051
West Africa
0–6 1799 0.3997 2687 0.3315 4486 0.3558
6–12 839 0.2314 1395 0.2108 2234 0.2181
12–24 1195 0.2206 2132 0.2149 3327 0.2169
>24 1603 0.2206 2590 0.2290 4193 0.2336
Asia Pacific
0–6 176 0.0874 57 0.0679 233 0.0817
6–12 142 0.0785 55 0.0758 197 0.0676
12–24 238 0.0859 80 0.0628 318 0.0739
>24 654 0.0710 218 0.0604 872 0.0681
Latin America
0–6 109 0.1104 51 0.1266 160 0.1151
6–12 96 0.1054 42 0.1113 138 0.1071
12–24 176 0.1087 79 0.1172 255 0.1112
>24 629 0.1314 252 0.1161 881 0.1266
ART, antiretroviral therapy.
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Figure 1 Distribution of CD4 counts
at antiretroviral therapy initiation in the
Kenya, South Africa, West Africa, Asia
Pacific and Latin America cohorts.
Statistics for men are shown on the
left and women on the right.
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(defined by gender, CD4 and age categories) considered in the
current analyses (figure 3). The choice of the adjustment
based on the South African data is justified further in the
Discussion section. The revised estimates of mortality are
shown in figure 4. In all cases, even though the highest death
rates occur during the first 6 months after therapy initiation,
estimated death rates are lower than in Kenya and South
Africa. West Africa has the highest rates among these three
regions, Latin America is in the middle and Asia Pacific has
the lowest death rates among all regions considered.
DISCUSSION
This study summarises data from five regional consortia, three
in sub-Saharan Africa, one in Latin America and one in the
Asia Pacific region. As expected, the estimated death rates are
the highest in sub-Saharan Africa, with moderately high rates
in Latin America and low rates in Asia Pacific. As is widely pub-
lished, use of outreach information and linkages with vital
registries resulted in a substantial upward revision of all mortal-
ity estimates, particularly during the early months after initi-
ation of ART.16 17 19 24
With respect to CD4 count at the start of therapy, the
results are consistent with expectation. Patients who start
therapy at lower CD4 counts, particularly <100 cells/μl, have
significantly higher death rates compared with those starting at
CD4 counts above 100 cells/μl. Men also have higher estimated
mortality in all strata identified by gender, age and CD4
counts. A consistent trend emerges with regard to age as well.
Figure 2 Adjusted estimates of mortality by age, gender and CD4 count antiretroviral therapy (ART) initiation in the Kenyan and South African cohorts.
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Mortality is highest among the 15–24 age group and the
over-45 group and relatively lower in the other two groups.
Mortality adjustments did not change the overall trend of
mortality. However, the magnitude of the revision was such as
to significantly undermine the veracity of published estimates
generated in a similar context but without the benefit of
patient outreach or linkage to vital registries. This observation
underlines the need of both the availability of post-dropout
vital status information and the usefulness of mathematical
adjustment methods to generate as accurate mortality esti-
mates as possible. While mortality was, overall, lower in the
highest CD4 group (>500 cells/μl), the adjustments in this
category were the highest in the Southern Africa group. This
suggests a separate mortality pattern in patients starting ART
with higher CD4 counts, a not unsurprising result given that
ART is initiated in these patients only when there is evidence
of serious health problems. At the very least, this observation
implies that current estimates of response to therapy (including
mortality) cannot be used to predict what the impact of initiat-
ing ART at higher CD4 counts will be as advocated in newer
treatment guidelines.
When outreach data are not available, our options are limited
with regard to generating valid adjustments of mortality from
passive recording of vital status information. Adjusting the
Figure 3 Correction factors for mortality estimates derived from the Kenya and South Africa cohort data. ART, antiretroviral therapy.
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Figure 4 Adjusted death rates among men (left) and women (right panels) in West Africa, Asia Pacific and Latin America. ART, antiretroviral
therapy.
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analyses by incorporating predictive factors collected prior to
dropout is not expected to work as the loss to follow-up is
informative41 (ie, it is related to the likelihood of the outcome
even after adjusting for predictive factors that are commonly
collected prior to dropping out). An alternative is to exploit the
inverse relationship between the levels of dropout and the rela-
tive hazard between dropouts and non-drop outs31 to impute
the rate among individuals who are not retained in care.
However, this approach requires significant contextual knowl-
edge about the programme and may thus be questionable par-
ticularly in settings where high dropout is not associated with
rapid scale-up and/or there are limited alternative care and
treatment programmes in the area.24
To overcome this difficulty and derive mortality adjustments
in the three regions without available patient outreach data (ie,
the West Africa, Asia Pacific and Latin America regions), we used
a hybrid method consistent with the approach in Brinkhof and
colleagues29 rather than the nomogram approach proposed by
Egger et al.31 Given the significant differences in the resulting
adjustment when using the Kenya versus the South Africa cor-
rection factors, it is a valid question which of the two should be
generally used. While, in absolute terms, the resulting mortality
estimates were similar after employing either adjustment
method, we ended up presenting the South Africa-derived cor-
rection in this manuscript. The reason for this is an idiosyncrasy
of the Kenya cohort in which patients who have started ART
more recently are followed particularly intensively compared
with those who have been on treatment for longer periods.16 17
This may have resulted in an undersampling in patients with a
longer follow-up and may be the reason for the diminishing
adjustment levels during the time intervals past 6 months. By
contrast, access to vital registries is expected to be virtually
unchanged regardless of the duration of therapy. This specula-
tion along with the fact that both adjustment methods pro-
duced virtually identical adjustment coefficients during the first
6 months from the start of therapy resulted in us choosing the
South Africa correction factors to adjust the mortality estimates
in regions outside East and Southern Africa.
The approach applied here has a number of limitations: It is
not known whether adjustments developed in sub-Saharan
Africa will be applicable in settings outside the continent, par-
ticularly in developed countries such as Japan, Hong Kong or
Taiwan. For example, patients who are lost to follow-up in
Buenos Aires, Argentina (a middle-income setting), tended to
have better markers of health at antiretroviral initiation than
patients who remained in care,42 which suggests that naive
analyses could actually be overestimating death rates. In add-
ition, rates of loss to follow-up are different between regions,
something that the nomogram approach by Egger and collea-
gues31 takes into account but our adjustment method does not.
With that said, without available tracing data it is impossible
to really know what is happening to those who are lost from
observation, and the adjustment methods outlined here repre-
sent at least a reasonable starting point given the potentially
significant under-reporting of death rates even in middle- or
high-income settings.
However, even within regions with available outreach data
biases exist. In East Africa, mortality adjustments were based
on patient tracing programmes which do not trace a random
sample of the patients who were lost to follow-up19 but are
imbedded into existing clinically-oriented patient outreach
efforts.18 19 25 The fact that the patients to be traced are not
identified in a random fashion and, in addition, not all sought
after patients are successfully located, raises significant
questions about the representativeness of the located sub-
sample compared with the overall group of patients lost from
observations. The South African vital registry linkage methods
are also subject to this bias. Thus, the accuracy of the adjusted
estimates is put into question, particularly in light of reports
where the hardest to locate patients are also those at the
highest risk strata.18 In the analyses presented in this paper we
made the (largely untestable) assumption that the patients
who are successfully located, either through physical outreach
or successful linkage with the vital registry, do not differ sys-
tematically from those who are not and can thus be regarded
as a random sample of all patients who are lost to follow-up.
A final consideration is the degree of confidence that one
should attach to these results. We would expect that the
adjustments produced in the Kenya and South African cohorts
would be fairly accurate, particularly in the first 6 months from
treatment initiation, given the enormity of the available data,
which ensures that the mathematical properties of the models
(ie, their ‘asymptotics’) would be fulfilled. Confidence in the
mortality estimates would be decreasing in the case of West
Africa and, even further, in the Latin America and Asia Pacific
regions, which include highly variable epidemics. In particular,
the better survival seen in the Asian data, which includes both
developed and developing countries, should not be overinter-
preted. The cohorts which comprise these data are not national
treatment programmes, and survival in these relatively small
numbers of patients in individual countries should probably
not be extrapolated to survival outcomes across the entire
region. For example, data from the China National Free
Antiretroviral Treatment Program show survival more similar
to outcomes in Africa.43 The survival seen in the Asia data in
this paper is perhaps better interpreted as indicative of what
can be achieved in well resourced individual treatment sites.
The overall conclusion of this manuscript is thus twofold:
From a clinical perspective, we continue to observe a large
number of patients start therapy at very low CD4 counts, even
in middle- and high-income settings, and these patients experi-
ence high levels of mortality particularly during the first
6-month period from treatment initiation. With this realisation,
it is imperative to increase efforts to identify these patients and
bring them to care. From an epidemiological and public-health
perspective, patient outreach and vital linkage methods should
be considered for inclusion in all HIV care and treatment pro-
grammes because of the strong association between loss to
follow-up with adverse clinical outcomes and the resulting
potentially significant underestimation of mortality.
Main findings
▸ Despite advances in antiretroviral treatment coverage, many
patients start treatment at very low CD4 counts and
experience significant mortality during the first 6 months
after treatment initiation.
▸ Active patient tracing and linkage with vital registries are
critical for deriving accurate estimates of mortality,
particularly in low- and middle-income settings.
▸ In addition to the youngest patients, older patients have high
death rates. With extended survival due to the expansion of
ART coverage and the resulting ageing of the HIV/AIDS
population, the impact of age on mortality needs to be
considered in decision and policy making.
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